✦ LIBER ✦

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

✍ Scribed by Moon, Yong; Lee, Soohyeon; Park, Byeong-Woo; Kim, Eun-Kyung; Kim, Seung; Koo, Ja; Park, Seho; Kim, Min; Chung, Hyun; Kim, Joo-Hang; Sohn, Joohyuk

Book ID: 121593186
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 185 KB
Volume: 13
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-13-583

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III Trial Comparing Doxorubicin Pl

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

✍ Jones, S. E.; Savin, M. A.; Holmes, F. A.; O'Shaughnessy, J. A.; Blum, J. L.; Vu 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 372 KB

Doxorubicin/Pemetrexed Followed by Docet

Doxorubicin/Pemetrexed Followed by Docetaxel Versus Doxorubicin/Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early-Stage Breast Cancer: A Randomized Phase II Trial

✍ Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez- 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 88 KB

3–59 Phase III Trial Comparing Doxorubic

3–59 Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclosphosphamide As Adjuvant Therapy for Operable Breast Cancer

✍ Denlinger, C.S.; Goldstein, L.J. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 71 KB

0178 Results of clinical endpoints of a

0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer

✍ A. Schneeweiss; A. Ruiz; P. Rovira; A. Bottini; A. Manikhas; J. Wacker; T. Schum 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Phase II Study of Neoadjuvant Docetaxel/

Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with Stage II/III Breast Cancer

✍ Steven A. Limentani; Adam M. Brufsky; John K. Erban; Mohammed Jahanzeb; Deborah 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 490 KB

Toxicity of Dose-Dense Docetaxel Followe

Toxicity of Dose-Dense Docetaxel Followed by Doxorubicin with Cyclophosphamide as Adjuvant Therapy for Breast Cancer in a Phase II Study

✍ Rosemary Lambert-Falls; Susan Modugno 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB